Literature DB >> 2549567

Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres.

S Houle1, T K Yip, F A Shepherd, L E Rotstein, K W Sniderman, E Theis, R H Cawthorn, K Richmond-Cox.   

Abstract

The potential use of yttrium-90 glass microspheres in the treatment of hepatocellular carcinoma was assessed in a pilot study of seven patients. The Y-90 microspheres were injected via a hepatic artery catheter. In this group of patients, no toxicity was observed for absorbed doses of between 5,000 and 10,000 cGy to the liver and up to 32,000 cGy to the tumor itself. Tumor response was seen only at the higher absorbed doses. The new Y-90 glass microspheres can safely deliver large doses of internal radiation to hepatic tumors as long as extrahepatic shunting can be excluded. Extrahepatic shunting will be the main limitation to this form of radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549567     DOI: 10.1148/radiology.172.3.2549567

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  24 in total

1.  Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies.

Authors:  Simon S M Ng; Simon C H Yu; Paul B S Lai; W Y Lau
Journal:  Dig Dis Sci       Date:  2008-03-05       Impact factor: 3.199

2.  Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma.

Authors:  Lu Liu; Zao Jiang; Gao-Jun Teng; Ji-Zhi Song; Dong-Sheng Zhang; Qing-Ming Guo; Wen Fang; Shi-Cheng He; Jin-He Guo
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

3.  Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.

Authors:  Alireza Karimian; Nathan T Ji; Hong Song; George Sgouros
Journal:  Cancer Res       Date:  2019-11-26       Impact factor: 12.701

4.  90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.

Authors:  Maren Bienert; Barry McCook; Brian I Carr; David A Geller; Mike Sheetz; Cecilia Tutor; Nikhil Amesur; Norbert Avril
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-17       Impact factor: 9.236

Review 5.  Therapeutic radionuclides in nuclear medicine: current and future prospects.

Authors:  Chai-Hong Yeong; Mu-hua Cheng; Kwan-Hoong Ng
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

6.  Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours.

Authors:  S Ho; W Y Lau; T W Leung; M Chan; Y K Ngar; P J Johnson; A K Li
Journal:  Eur J Nucl Med       Date:  1996-08

Review 7.  Treatment of hepatocellular carcinoma by means of radiopharmaceuticals.

Authors:  Bieke Lambert; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08       Impact factor: 9.236

8.  Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.

Authors:  M A D Vente; M Wondergem; I van der Tweel; M A A J van den Bosch; B A Zonnenberg; M G E H Lam; A D van Het Schip; J F W Nijsen
Journal:  Eur Radiol       Date:  2008-11-07       Impact factor: 5.315

9.  Preparation of phosphorus-containing silica glass microspheres for radiotherapy of cancer by ion implantation.

Authors:  M Kawashita; F Miyaji; T Kokubo; Y Suzuki; K Kajiyama
Journal:  J Mater Sci Mater Med       Date:  1999-08       Impact factor: 3.896

10.  First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation.

Authors:  Etienne Garin; Yan Rolland; Eveline Boucher; Valérie Ardisson; Sophie Laffont; Karim Boudjema; Patrick Bourguet; Jean-Luc Raoul
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.